Ipsen shares fall 6.6% after FDA approves generic hormone-drug rival
AI Summary- Ipsen shares fell after the FDA approved a generic competitor to its flagship hormone drug.
- Shares dropped 6.6% to 145.60 euros, reaching a seven-month low.
- Ipsen became the worst performer in the Europe-wide Stoxx 600 index.